Loading
A phase 3 trial of Socazolimab run by Lee's Pharmaceutical Limited in cervical cancer, now recruiting.
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06459687 by Lee's Pharmaceutical Limited, with 440 participants planned, started 2024-11-28. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/